Harvey Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Harvey Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,040	Closed	-$102K	–	82
2019 Q1	$102K	Sell	3,040 -80	-3%	-$2.67K	0.05%	77
2018 Q4	$91K	Hold	3,120	–	–	0.05%	75
2018 Q3	$192K	Hold	3,120	–	–	0.08%	75
2018 Q2	$230K	Hold	3,120	–	–	0.09%	75
2018 Q1	$204K	Hold	3,120	–	–	0.08%	78
2017 Q4	$262K	Sell	3,120 -850	-21%	-$83.4K	0.09%	76
2017 Q3	$458K	Buy	+3,970	New	+$418K	0.18%	61

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harvey Capital Management's BLCM Position: Q2 2019 in Review

Harvey Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 3,040 shares — an estimated $102K sold.

Harvey Capital Management first reported a position in BLCM in Q3 2017 and held it in 7 quarters. The position peaked at $458K in Q3 2017. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Harvey Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Harvey Capital Management sold 3,040 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $102K.
Harvey Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2017 and held it in 7 quarters.
Harvey Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $458K in Q3 2017.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Harvey Capital Management's 13F filing for Q2 2019, filed 23 Jul 2019.